TY - JOUR
T1 - Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy
AU - Dottore, Giovanna Rotondo
AU - Torregrossa, Liborio
AU - Caturegli, Patrizio
AU - Ionni, Ilaria
AU - Sframeli, Angela
AU - Sabini, Elena
AU - Menconi, Francesca
AU - Piaggi, Paolo
AU - Sellari-Franceschini, Stefano
AU - Nardi, Marco
AU - Latrofa, Francesco
AU - Vitti, Paolo
AU - Marcocci, Claudio
AU - Basolo, Fulvio
AU - Marino, Michele
N1 - Funding Information:
Funding/Support: The study was funded by the University of Pisa Fondi di Ateneo (Dr Marinò).
PY - 2018/6
Y1 - 2018/6
N2 - IMPORTANCE Graves orbitopathy (GO) responds to immunosuppressive treatments when clinically active but poorly when inactive. In other autoimmune diseases, response has been ascribed to a reduction in lymphocytes infiltrating the target organ. It is not known whether active vs inactive GO differs in this regard, which would help in understanding the link between GO immunologic features and clinical behavior. OBJECTIVE To investigate the association between orbital lymphocytic infiltrate and GO clinical features. DESIGN, SETTING, AND PARTICIPANTS A cohort study aimed at assessing the extent and immunohistochemical phenotype of orbital lymphocytes and associating it with the ophthalmologic features of GO, especially its clinical activity score (CAS), was conducted at a tertiary referral center. Twenty consecutive patients with GO who underwent orbital decompression were included. The study was conducted from January 1 to May 31, 2017. EXPOSURES Orbital tissue histology and immunohistochemistry testing as well as ophthalmologic evaluation. MAIN OUTCOMES AND MEASURES Association between CAS and orbital lymphocytes, analyzed as total number of lymphocytes and main lymphoid subsets. RESULTS The patient population included 8 men and 12 women, all of white race, with a mean (SD) age of 46 (13) years. With an established cutoff value of 300 lymphoid cells per tissue sample, lymphocytes above this value were found in orbital tissues of 9 of 20 patients (45%), often organized into distinct foci. The lymphocytes comprised a mixture of T (CD3-positive) and B (CD20-positive) cells, suggesting a mature, polyclonal autoimmune response. In a simple linear regression model, the total number of lymphocytes, as well as the number of CD3- and CD20-positive subsets, correlated with CAS (R = 0.63; 95% CI, 0.27-0.84; P = .003; R = 0.59; 95% CI, 0.20-0.82; P = .006; and R = 0.65; 95% CI, 0.30-0.85; P = .002, respectively). In a multiple linear regression model, lymphocytes maintained their effect on CAS when adjusted for 2 additional variables that were correlated with CAS-smoking and GO duration-highlighting even more the important role of orbital lymphocytes in affecting CAS (total number: R = 0.58; 95% CI, 0.18-0.82; P = .01; CD3-positive: R = 0.58; 95% CI, 0.17-0.82; P = .01; and CD20-positive: R = 0.59; 95% CI, 0.19-0.83; P = .01). CONCLUSIONS AND RELEVANCE This study shows a correlation between T and B lymphocytes infiltrating orbital tissues and the activity of GO, possibly enhancing our understanding of the association between GO immunologic features and clinical expression.
AB - IMPORTANCE Graves orbitopathy (GO) responds to immunosuppressive treatments when clinically active but poorly when inactive. In other autoimmune diseases, response has been ascribed to a reduction in lymphocytes infiltrating the target organ. It is not known whether active vs inactive GO differs in this regard, which would help in understanding the link between GO immunologic features and clinical behavior. OBJECTIVE To investigate the association between orbital lymphocytic infiltrate and GO clinical features. DESIGN, SETTING, AND PARTICIPANTS A cohort study aimed at assessing the extent and immunohistochemical phenotype of orbital lymphocytes and associating it with the ophthalmologic features of GO, especially its clinical activity score (CAS), was conducted at a tertiary referral center. Twenty consecutive patients with GO who underwent orbital decompression were included. The study was conducted from January 1 to May 31, 2017. EXPOSURES Orbital tissue histology and immunohistochemistry testing as well as ophthalmologic evaluation. MAIN OUTCOMES AND MEASURES Association between CAS and orbital lymphocytes, analyzed as total number of lymphocytes and main lymphoid subsets. RESULTS The patient population included 8 men and 12 women, all of white race, with a mean (SD) age of 46 (13) years. With an established cutoff value of 300 lymphoid cells per tissue sample, lymphocytes above this value were found in orbital tissues of 9 of 20 patients (45%), often organized into distinct foci. The lymphocytes comprised a mixture of T (CD3-positive) and B (CD20-positive) cells, suggesting a mature, polyclonal autoimmune response. In a simple linear regression model, the total number of lymphocytes, as well as the number of CD3- and CD20-positive subsets, correlated with CAS (R = 0.63; 95% CI, 0.27-0.84; P = .003; R = 0.59; 95% CI, 0.20-0.82; P = .006; and R = 0.65; 95% CI, 0.30-0.85; P = .002, respectively). In a multiple linear regression model, lymphocytes maintained their effect on CAS when adjusted for 2 additional variables that were correlated with CAS-smoking and GO duration-highlighting even more the important role of orbital lymphocytes in affecting CAS (total number: R = 0.58; 95% CI, 0.18-0.82; P = .01; CD3-positive: R = 0.58; 95% CI, 0.17-0.82; P = .01; and CD20-positive: R = 0.59; 95% CI, 0.19-0.83; P = .01). CONCLUSIONS AND RELEVANCE This study shows a correlation between T and B lymphocytes infiltrating orbital tissues and the activity of GO, possibly enhancing our understanding of the association between GO immunologic features and clinical expression.
UR - http://www.scopus.com/inward/record.url?scp=85048783002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048783002&partnerID=8YFLogxK
U2 - 10.1001/jamaophthalmol.2018.0806
DO - 10.1001/jamaophthalmol.2018.0806
M3 - Article
C2 - 29710102
AN - SCOPUS:85048783002
VL - 136
SP - 613
EP - 619
JO - JAMA Ophthalmology
JF - JAMA Ophthalmology
SN - 2168-6165
IS - 6
ER -